Диссертация (1140614), страница 14
Текст из файла (страница 14)
Haemost. – 2013. – Vol.109 (3). –P.479-487.47.Bovill E.G., Van der Vliet A. Venous valvular stasis-associated hypoxiaand thrombosis: what is the link? // Annu Rev. Physiol. – 2011. – Vol.73. – P.527-545.48.Brand B., Graf L. New anticoagulants - direct thrombin inhibitors //Ther. Umsch. – 2012. – Vol.69 (11). – P.643-649.9549.Byrne S., Weaver D.T. Review of thromboembolic prophylaxis inpatients attending Cork University Hospital // Int. J. Clin. Pharm. – 2013. – Vol.35 (3).– P.439-446.50.Calvo Romero J.M., Lima Rodriguez E.M.
New oral anticoagulants inthe treatment of venous thromboembolic disease // Semergen. - 2013. – Vol.39 (3). –P.146-149.51.Calvo Romero J.M. Recurrence risk in venous thromboembolic diseaseafter anticoagulation discontinuation // Med. Clin. (Barc). – 2013. – Vol.140 (7). –P.310-313.52.Campello E., Spiezia L., Radu C. et al. Circulating microparticles incarriers of factor V Leiden with and without a history of venous thrombosis // Thromb.Haemost. – 2012. – Vol.108 (4). – P.633-639.53.Caprini J. A. Individual risk assessment is the best strategyfor thromboembolic prophylaxis // Dis.
Mon. – 2010. – Vol.56 (10). – P.552-559.54.Caraco Y., Blotnick S., Muszkat M. CYP2C9 Genotype-guided warfarinprescribing enhances the efficacy and safety of anticoagulation: A prospectiverandomized controlled study // Clinical Pharmacology and Therapeutics. – 2007. –Vol.83. – P.460-470.55.Carcas A.J., Borobia A.M., Velasco M. et al.Efficiency andeffectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versususualcareinpatientswith venous thromboembolic diseaseinitiatingoralanticoagulation: study protocol for a randomized controlled trial // Trials. – 2012. –Vol.13 (239).56.Casais P., Meschengieser S.S., Sanchez-Luceros A., Lazzari M.A.Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality oflife // Curr.
Med. Res. Opin. – 2005. – Vol.21 (7). – P.1085–1090.57.Chaireti R., Jennersj C., Lindahl T.L. Is thrombin generation at the timeof an acute thromboembolic episode a predictor of recurrence? A 7-year follow-up //Thromb. Res. - 2013. – Vol.131 (2). – P.135-139.9658.ChanC.M.,ShorrA.F.Economicandoutcomesaspectsof venous thromboembolic disease // Crit. Care Clin. – 2012. – Vol.28 (1). – P.113123.59.Cios D.A., Baker W.L., Sander S.D.
et al. Evaluating the impact ofstudy-level factors on warfarin control in U.S.-based primary studies: a meta-analysis// Am. J. Health Syst. Pharm. – 2009. – Vol.12 (10). – P.916–925.60.Clemens A., Haertter S., Friedman J. et al. Twice daily dosing ofdabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification //Curr. Med. Res. Opin.
– 2012. – Vol.28 (2). – P.195–201.61.Coleman D.M., Wakefield T.W. Biomarkers for the diagnosis of deepvein thrombosis // Expert. Opin. Med. Diagn. - 2012. – Vol.6 (4). – P.253-257.62.Collaborative meta-analysis of randomised trials of antiplatelet therapyfor prevention of death, myocardial infarction, and stroke in high risk patients.Antithrombotic Trialists’ Collaboration // BMJ.- 2002. – Vol.324.
– P.71–86.63.Connolly G.C., Khorana A.A. Emerging risk stratification approaches tocancer associated thrombosis: risk factors, biomarkers and a risk score // Thromb Res.-2010. - Vol.125, Suppl.2.64.Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients withatrial fibrillation // N Engl.
J. Med. - 2011. – Vol.364 (9). – P.806–817.65.Cook D, Meade M, Guyatt G. et al. Clinically important deep veinthrombosis in the ICU: A survey of intensivists // Critical Care. - 2008. – Vol. 8. –P.145–152.66.Cossetto D.J., Goudar A., Parkinson K. Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolicprophylaxis for total kneeand hip arthoplasty // J. Orthop. Surg (Hong Kong).
– 2012. – Vol.20 (3). – P.341-343.67.CraftM.K.,ReedM.J.Venous thromboembolic diseaseandhematologic considerations in obesity // Crit. Care Clin. – 2010. – Vol.26 (4). –P.637640.68.Dahl O.E. New oral antithrombotics: focus on dabigatran, an oral,reversible direct thrombin inhibitor for the prevention and treatment of venous and97arterial thromboembolic disorders // Vasc.
Health Risk Manag. – 2012. – Vol.8. – P.4557.69.D’Andrea G., D’Ambrosio R.L., Di Perna P. et al. A polymorphism intheVKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin // Blood. – 2005. – Vol. 105 (2). – P.645–649.70.Davis N.J., Billett H.H., Cohen H.W., Arnsten J.H. Impact ofadherence, knowledge, and quality of life on anticoagulation control // Ann.Pharmacother. - 2005. – Vol.39 (4).
– P.632–636.71.Deitelzweig S.B., Becker R., Lin J., Benner J. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venousthromboembolism // Thromb. Haemost. - 2008. – Vol.100 (5). – P.810-820.72.Den Exter P.L., Van Es J., Klok F.A. et al. Risk profile and clinicaloutcome of symptomatic subsegmental acute pulmonary embolism // Blood. – 2013. Jun 4.
[Epub ahead of print].73.Dennis M., Cranswick G., Deary A. et al. Effectiveness of thigh-lengthgraduated compression stockings to reduce the risk of deep vein thrombosis after stroke(CLOTS trial 1): a multicentre, randomised controlled trial // Lancet.– 2009. –Vol.373(9679). – P.1958-1965.74.Dentali F., Di Minno M.N., Gianni M. et al. The role of the metabolicsyndrome in patients with provoked venous thromboembolic events // Thromb.Haemost. - 2013. –Vol.109 (4). – P.759-761.75.Dentali F., Sironi A.P., Ageno W. et al.
Relationship between ABOblood group and hemorrhage: a systematic literature review and meta-analysis // Semin.Thromb. Hemost. – 2013. – Vol.39(1). – P.72-82.76.Dentali F., Squizzato A., Caprioli M. et al. Prevalence of arterialand venous thromboembolic events in diabetic patients with and without the metabolicsyndrome: a cross sectional study // Thromb. Res. - 2011.- Vol.127 (4).
– P.299-302.77.Diener H.C., Stanford S., Abdul-Rahim A. et al. Anti-thrombotictherapy in patients with atrial fibrillation and intracranial hemorrhage // Expert Rev.Neurother. - 2014. – Vol.4. – P.1-10.9878.Ducros V., Barro C., Yver J. et al. Should plasma homocysteine be usedas a biomarker of venous thromboembolism? A case-control study // Clin.
Appl.Thromb. Hemost. - 2009. – Vol.15 (5). – P. 517-522.79.Eberle B.M., Schniriger B., Inaba K. et al. Thromboembolic prophylaxiswith low-molecular-weight heparin in patients with blunt solid abdominal organ injuriesundergoing nonoperative management: current practice and outcomes // J. Trauma. –2011. – Vol.70 (1). – P.141-146.80.Ebright J., Mousa S.A. Oral Anticoagulants and Status of Antidotes forthe Reversal of Bleeding Risk // Clin. Appl.
Thromb. Hemost. – 2014. - Aug 12.[Epub ahead of prin].81.EuropeanMedicinesAgency.Eliquis-SummaryofProductCharacteristics. London: European Medicines Agency; 2013. Available from:http://www.ema.europa.eu/docs/en_GB/document_library.82.Fernandez Capitin M.C. Epidemiology of thromboembolic diseases:atrial fibrillation, venous thromboembolic disease and acute coronary syndrome // Med.Clin. (Barc). - 2012. – Vol.139, Suppl. 2. – P.4-9.83.Flaker G.C., Eikelboom J.W., Shestakovska O. et al.
Bleeding duringtreatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable forwarfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillationpatients who have failed or are unsuitable for vitamin K antagonist treatment(AVERROES) trial // Stroke.
– 2012. – Vol.43 (12). – P.3291–3297.84.Frania A., De Sousa J.A., Felicissimo P., Ferreira D. Venousthromboembolism's risk assessment: rationale, objectives, and methodology - the ARTEstudy // Acta Med. Port. – 2011. – Vol.24, Suppl.2. – P.575-582.85.Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratificationschemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation:the Swedish Atrial Fibrillation cohort study // Eur. Heart J. - 2012.
– Vol.33 (12). –P.1500–1510.86.Fries D. Thrombosis prophylaxis in critically ill patients // Wien MedWochenschr. – 2011. – Vol.161 (3-4). – P.68-72.9987.Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006guidelines for the management of patients with atrial fibrillation // Circulation.- 2006.– Vol.12 (7). - P.257–354.88.Gabriel F., Portolis O., Labis M.
et al. RIETE Investigators. Usefulnessof thrombophilia testing in venous thromboembolic disease: findings from the RIETEregistry // Clin. Appl. Thromb. Hemost. – 2013. – Vol.19 (1). – P.42-47.89.Gage B.F. Can we rely on RE-LY? // N Engl J. Med. - 2009. – Vol.361.– P.1200–1202.90.Gage B.F., Eby C., Johnson J.A. at al. Use of pharmacogenetic andclinical factors to predict the therapeutic dose of warfarin // Clinical Pharmacology andTherapeutics. - 2008. – Vol.84. – P.326-331.91.Galanaud J.P., Genty C., Sevestre M.A. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
